EpiCept Corporation Regains Rights to Azixa® From Licensee Myrexis, Inc.

Published: Sep 05, 2012

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today it has received notice of termination, effective as of August 28, 2012, of its License and Collaboration Agreement with Myrexis, Inc. Among the compounds that had been licensed to Myrexis under the terminated agreement was EpiCept's anti-cancer drug candidate Azixa®.

Back to news